Market Cap | 423.50M | P/E | - | EPS this Y | 31.70% | Ern Qtrly Grth | - |
Income | -159.13M | Forward P/E | -18.33 | EPS next Y | 38.40% | 50D Avg Chg | -1.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | 33.00% |
Dividend | N/A | Price/Book | 40.24 | EPS next 5Y | - | 52W High Chg | -19.00% |
Recommedations | 1.70 | Quick Ratio | 0.87 | Shares Outstanding | 23.30M | 52W Low Chg | 106.00% |
Insider Own | 37.01% | ROA | -66.19% | Shares Float | 11.72M | Beta | 0.29 |
Inst Own | 32.23% | ROE | - | Shares Shorted/Prior | 1.26M/1.33M | Price | 1.65 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 1,276,037 | Target Price | 39.91 |
Oper. Margin | - | Earnings Date | Aug 12 | Volume | 1,001,706 | Change | -1.20% |
Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with BioLexis Pte. Ltd. and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
HC Wainwright & Co. | Buy | May 17, 24 |
BTIG | Buy | Mar 27, 24 |
HC Wainwright & Co. | Buy | Mar 25, 24 |
Chardan Capital | Buy | Feb 15, 24 |
Guggenheim | Buy | Jan 25, 24 |
Brookline Capital | Buy | Jan 25, 24 |
Ascendiant Capital | Buy | Dec 29, 23 |
Capital One | Overweight | Dec 27, 23 |
HC Wainwright & Co. | Buy | Nov 3, 23 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
Dagnon Terry | Chief Operations Off.. Chief Operations Officer | Apr 20 | Sell | 1.135 | 520,000 | 590,200 | 653,058 | 04/21/23 |
Evanson Jeff | Chief Commercial Off.. Chief Commercial Officer | Jan 20 | Sell | 1.11 | 267,000 | 296,370 | 745,975 | 01/24/23 |
Evanson Jeff | Chief Commercial Off.. Chief Commercial Officer | Jan 17 | Sell | 1.26 | 164,155 | 206,835 | 1,012,975 | 01/19/23 |
HILZINGER KURT J | Director Director | Oct 04 | Buy | 1.26 | 111,203 | 140,116 | 473,117 | 10/05/22 |
Dagnon Terry | Chief Operating Offi.. Chief Operating Officer | Jun 21 | Buy | 1.05 | 10,000 | 10,500 | 1,173,058 | 06/23/22 |
TRENARY C RUSSELL III | CEO and President CEO and President | Jun 21 | Buy | 1.06 | 19,925 | 21,120 | 54,925 | 06/23/22 |
HILZINGER KURT J | Director Director | Mar 01 | Buy | 1.69 | 27,708 | 46,827 | 273,117 | 03/03/22 |
HILZINGER KURT J | Director Director | Feb 24 | Buy | 1.53 | 47,160 | 72,155 | 245,409 | 02/28/22 |
HILZINGER KURT J | Director Director | Feb 22 | Buy | 1.47 | 175,132 | 257,444 | 198,249 | 02/23/22 |